Reported Friday, Sep 25 - 4:52am EDT (TheFly subscription required to read more.)

Reported Thursday, Sep 24 - 9:07pm EDT (TheFly subscription required to read more.)

B. Riley rates Precigen Buy on Papzimeos, the first FDA-approved adult RRP therapy, plus Q2 profit and management’s year-end cash break-even goal.

Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.

For the first time, the FDA has

Precigen has received FDA platform technology designation for its AdenoVerse platform, enabling faster development of innovative therapies targeting HPV-related cancers.

Reported Monday, Sep 21 - 7:03am EDT (TheFly subscription required to read more.)

JMP Securities restated their market outperform rating on shares of Precigen (NASDAQ:PGEN – Free Report) in a research report report published on Thursday morning,Benzinga reports. JMP Securities currently has a $6.00 price objective on the biotechnology company’s stock. Other analysts have also recently issued reports about the company. Wall Street Zen cut Precigen from a […]

Phone lines open for a 4:30 p.m. ET call as the biotech reviews first-quarter results and business updates; event details are posted online.

Key Takeaways Investors surge into Precigen Partnerships drive PGEN's growth Regulators approve PGEN products Analysts call PGEN a buy As the Indian stock market continues to defy gravity, with the Sensex breaching the 60,000 mark for the first time, one company stands out as a shining example of the sector's potential: Precigen (PGEN). This biotechnology firm has been quietly making waves in the industry, and investors are taking notice. In the past year alone, PGEN's stock has surged by over 200%, outpacing the broader market's growth. But what's behind this remarkable performance, and why are analysts calling Precigen a "buy"?

Precigen has announced significant advancements in its gene therapy PRGN-2012 aimed at treating recurrent respiratory papillomatosis (RRP), with FDA approval pending.

The FDA granted an unexpected full approval to Precigen's treatment for a rare disease caused by human papillomavirus, or HPV — a decision that came earlier than anticipated.

💥 Overnight-Ready CAR-T? One of the standout presentations at #ASGCT2025 came from Precigen, highlighting their UltraCAR-T platform and PRGN-3008 construct ; a promising approach that combines same-d...

Precigen’s PAPZIMEOS therapy is transforming the lives of adults with recurrent respiratory papillomatosis, eliminating endless surgeries.

Reported Tuesday, Aug 25 - 7:04am EDT (TheFly subscription required to read more.)

What PRECIGEN, INC. changed in their own words, quarter over quarter.

Reported Wednesday, Aug 5 - 6:01am EDT (TheFly subscription required to read more.)

Precigen meldet überraschenden Quartalsgewinn dank starkem PAPZIMEOS-Absatz. Die Gentherapie etabliert sich als Standard und treibt das Wachstum.

In the second quarter of 2026, Precigen reported remarkable growth driven by PAPZIMEOS, showcasing the company's strong commercial momentum and expanding reach.

Reported Tuesday, Aug 4 - 4:20pm EDT (TheFly subscription required to read more.)

Precigen (Nasdaq: PGEN) reported second quarter 2026 net product revenue of $53.1 million from PAPZIMEOS, more than double the prior quarter, driving total revenue to $55.0 million and net income of $20.1 million ($0.05 diluted EPS) versus a prior-year net loss of $26.6 million.For the first six months of 2026, total revenue reached $78.2 million, including $74.7 million from PAPZIMEOS, generating net income of $12.1 million compared with a $80.8 million loss a year earlier. Cash, cash equivalents and investments totaled $38.7 million at June 30, 2026, and, according to Precigen, together with anticipated PAPZIMEOS revenue are expected to fund operations through cash flow break-even by year-end 2026.PAPZIMEOS adoption includes well over 500 patient hub enrollments, payer coverage across about 315 million US lives, a permanent J-code (J3404), and seven-year FDA market exclusivity. An EMA marketing application is under review and a redosing study is enrolling.

Reported Tuesday, Aug 4 - 3:19pm EDT (TheFly subscription required to read more.)